ALX Oncology Advances CD47-Targeting Breast Cancer Program

ALX Oncology Advances CD47-Targeting Breast Cancer Program
ALX Oncology announced encouraging progress in its ASPEN-09 clinical trial, focusing on evorpacept, a CD47-targeting therapeutic candidate. The company expects to present interim data from approximately eighty patients by mid-2027, with particular attention on the CD47-high HER2-positive breast cancer cohort. This patient population has demonstrated a median progression-free survival of twenty-two months, suggesting potentially durable clinical benefit. The CD47 pathway represents an emerging immunotherapy approach that aims to enhance the body's natural ability to recognize and eliminate cancer cells. These interim results position evorpacept as a meaningful therapeutic option in the competitive landscape of HER2-positive breast cancer treatments.